TABLE 2.
Antifungal activities of fluconazole and itraconazole against BSIs of Candida spp. from three geographic regions
| Country | No. of isolates | Antifungal agent | MIC (μg/ml)
|
% Ra | ||
|---|---|---|---|---|---|---|
| Range | 50% | 90% | ||||
| United States | 203 | Fluconazole | 0.12–>128 | 0.5 | 16 | 2.5 |
| Itraconazole | 0.015–>8.0 | 0.12 | 1.0 | 11.3 | ||
| Canada | 61 | Fluconazole | 0.12–128 | 0.5 | 8.0 | 1.6 |
| Itraconazole | 0.015–0.5 | 0.12 | 0.25 | 3.3 | ||
| South America | 42 | Fluconazole | 0.12–>128 | 0.5 | 4.0 | 2.4 |
| Itraconazole | 0.015–8.0 | 0.12 | 0.25 | 2.4 | ||
| All | 306 | Fluconazole | 0.12–>128 | 0.5 | 8.0 | 2.3 |
| Itraconazole | 0.015–>8.0 | 0.12 | 0.5 | 8.5 | ||
a
% R, percent resistant by using the interpretive breakpoint criteria of NCCLS (5): fluconazole resistance, ≥64 μg/ml; itraconazole resistance, ≥1.0 μg/ml.